Please contact us anytime:
Predictive Neonatal Clinical Decicion Support Platform
Why invest in NeoPrediX?
- Digital Health
- Breakthrough prediction tool
- Global market potential
- Dedicated team of scientific and market experts
NeoPrediX will present at the following conferences
Investor Media Center
Multi-Center Observational Study
Clinical Decision Support Company NeoPrediX AG Completes Prospective Multi-Center Observational Study
Basel, Switzerland, Regensburg, Germany, and Ft. Lauderdale, FL, USA, May 25, 2022 – NeoPrediX AG, a privately held maternal and neonatal clinical decision support company focused on the development and commercialization of intelligent algorithms to predict dynamic progression of disease parameters during the first 1,000 days of life, announced at a poster presentation during the recent 48th Annual Meeting of the German Society for Neonatology and Pediatric Intensive Medicine held in Aachen, Germany, that a prospective multi-center observational study was formally completed.
NeoPrediX PRESENT AT BIOTECH SHOWCASE™ 2022
Breakthrough Prediction Software Platform of NeoPrediX shown at BIOTECH SHOWCASE
Regensburg, Germany. 22nd of December 2021 – NeoPrediX today announced that it will be presenting virtually at the Biotech Showcase™ 2022 conference with an online presentation.
Start-up company opens first US office
NeoPrediX starts marketing its prediction software platform in USA
November 15, 2021 - With the establishment of NeoPrediX USA in Fort Lauderdale (Florida) the German/Swiss NeoPredix AG starts its US business and pushes its internationalization strategy. The start-up company develops prediction software for hospitals and neonatal units based on scientific and clinical data as well as science-based algorithms.
Who is NeoPrediX
NeoPrediX AG test is a Swiss company located in Basel with subsidiaries in Regensburg, Germany and Ft. Lauderdale, Florida, USA.
Please feel free to contact us at any time for further questions and requests.